Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations
Journal of Pharmaceutical Policy and Practice (2018) 11:8
12 Pages Posted: 27 Sep 2019
Date Written: 2018
Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to discovery and early phase development of antibacterial therapies.
Suggested Citation: Suggested Citation